Edition:
United States

Merus NV (MRUS.OQ)

MRUS.OQ on NASDAQ Stock Exchange Global Market

14.74USD
15 Dec 2017
Change (% chg)

$0.39 (+2.72%)
Prev Close
$14.35
Open
$14.94
Day's High
$14.94
Day's Low
$14.44
Volume
2,522
Avg. Vol
5,917
52-wk High
$33.48
52-wk Low
$13.33

Select another date:

Thu, Nov 30 2017

BRIEF-Merus Nv Q3 Loss Per Share Eur 0.81

* MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS

BRIEF-Merus announces Q2 loss per share EUR 1.12

* Merus announces second quarter 2017 financial results and highlights recent progress

BRIEF-U.S. Court of Appeals for Federal Circuit affirms Merus' inequitable conduct claim against Regeneron

* Says U.S. Court of Appeals for Federal Circuit affirms Merus' inequitable conduct claim against regeneron

In win for Merus, court rules Regeneron obtained patent through deception

The Dutch biotech company Merus NV won an appeals court ruling on Thursday that a patent asserted against it by rival Regeneron Pharmaceuticals Inc is unenforceable because it was obtained through deception. In a 2-1 decision affirming a District Court judge, the U.S. Court of Appeals for the Federal Circuit said that the Regeneron patent, which relates to mice antibody technology, is unenforceable because a patent prosecutor at Regeneron withheld information from the U.S. Patent and Trademark O

BRIEF-Merus Q1 loss per share EUR 1.15

* Merus announces first quarter 2017 financial results and mid-year operating results

Select another date: